StemCell Therapy

MIAMI, May 27, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today a health update for two critically ill COVID-19 patients who were treated at Landmark Hospital in Athens, GA with the Companys Organicell Flow product. These patients were treated under the two recently approved Emergency Compassionate Use Investigational New Drug applications (eINDs) by the U.S. Food and Drug Administration (FDA).

Upon receiving FDA approval of the eIND on May 11, 2020, the Company and Landmark Hospital immediately treated the two critically ill COVID-19 patients, in their mid to late 70s, with Organicell Flow. Treatment with Organicell Flow resulted in a remarkable improvement in their clinical status, lung and renal function confirmed by follow up chest X-rays and lab data. These patients are no longer intubated, are alert and oriented with stable vital signs and oxygenation. Other organs such as the brain, heart and liver commonly affected in patients who had the SARS-CoV-2 virus have all shown progressive improvement in their function.

Dr. George Shapiro, Chief Medical Officer of Organicell stated, We are very pleased that Organicell Flow, administered intravenously, has to date met all of the primary objectives of safety and secondary clinical objectives of improved ICU status and reduction in the sequential organ failure assessment (SOFA) score.

Dr. Anthony Sagel, Chief of Medical Staff at Landmark hospital and treating physician for both patients said, The first patient has improved considerably and is now off the ventilator with normal appearing lungs on their chest X-ray. In addition, their mental status continues to improve along with normal kidney function. The second patient has also been systemically improving, including their kidney and respiratory function. Their acute delirium has improved, and is communicating well with family. Both patients are ready to be discharged from the ICU.

Worldwide clinical experiences have shown that the progressive decline in lung function is the main cause of death in patients infected with COVID-19 disease, and patients who are admitted to the ICU requiring mechanical ventilation (Intubation) has revealed high mortality rates. Both patients in the current study were severely ill with underlying health conditions and severe multi-organ failure. Under the defined protocols of the clinical trials, each of the above patients will continue to be monitored on their health vitals for a total period of 60 days. Based upon the continued favorable results, Organicell may seek other approvals to treat other severely ill patients.

About Organicell Regenerative Medicine, Inc.:

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The companys proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.

About Landmark Hospitals:

Landmark provides solutions for patients who face a hospital discharge, yet still require acute medical care. These patients require a higher level of care for a longer period than the average hospital offers; but they are not yet ready to transfer to a sub-acute care facility. Landmark brings exciting new technologies and experienced management for the primary task of providing patients with the best medical care available as they continue their journey toward healing. For more information regarding Landmark Hospitals, visit https://www.landmarkhospitals.com.

Forward-Looking Statements

Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the Securities Act), the Securities Exchange Act of 1934, as amended (the Exchange Act), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as will, believes, expects, potential or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Media Contact:RooneyPartnersMarion Janic646-537-5649mjanic@rooneyco.com

Excerpt from:
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients - GlobeNewswire

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Takara Bio USA, Inc. (TBUSA) announced that its parent company, Takara Bio Inc., has completed the construction of a new facility, the Center for Gene and Cell Therapy Processing II (CGCPII) in Shiga, Japan. The CGCPII has been operational since January 2020.

The CGCPII is an expansion of the Center for Gene and Cell Processing (CGCP), which was established in 2014 and designed specifically for the safe, efficient manufacture of gene and cell therapy products. Both facilities have received ISO 9001 certification. The CGCPII provides additional capacity for Good Manufacturing Practice (GMP) viral vector production, process development, aseptic filling, and quality-testing facilities, as well as room for future expansion.

With the addition of the CGCPII, Takara Bio is able to accommodate the growing demand for gene and cell therapies and will continue to enhance its services for biopharmaceuticals and regenerative medicine products under GMP and Good Gene, Cellular, and Tissue-based Products Manufacturing Practice (GCTP).

"Takara Bio is excited to increase our capacity to provide even more support to customers worldwide in the development of their regenerative medicine products. We have a history of developing products like RetroNectin reagent for regenerative medicine research, and we are building on that history with our expanded facility and service offerings," said Junichi Mineno, Chief Operating Officer, Takara Bio Inc.

With our state-of-the-art GMP manufacturing facilities in Japan and Europe, Takara Bio provides services for viral vector production, cell processing, clinical-grade human embryonic stem cell line derivation, quality testing, and cell banking. These gene and cell therapy manufacturing services, carried out by a global team of seasoned experts, provide support throughout the entire process of developing vital regenerative medicine products.

About Takara Bio

Takara Bio USA, Inc. (TBUSA) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.

Excerpt from:
Takara Bio Announces the Completion of a New GMP Facility for Manufacturing Gene and Cell Therapy Products - Business Wire

SAN DIEGO, May 26, 2020 /PRNewswire/ --ViaCyte, Inc., a privately held regenerative medicine company, today announced the close of an approximately $27 million private financing, part of the Series D preferred stock financing entered into in late 2018. Investors included, Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further advance the Company's multi-product candidate approach to develop medicines that have the potential to transform the way insulin-requiring diabetes is managed, potentially providing a functional cure for patients with type 1 diabetes.

Coinciding with the financing, the Company also appointed Ian F. Smithas Executive Chairperson. Mr. Smith was appointed to the Company's Board of Directors in July 2019 and succeeds Fred Middleton, who remains on the board.

Commenting on the financing, Paul Laikind, Ph.D., Chief Executive Officer and President of ViaCyte, said, "During these difficult times we are grateful for the continued support of our investors as well as our clinical trial participants, whose safety and health remains our focus and commitment. We are steadfast in our mission to deliver potentially life sustaining therapies for patients with insulin-requiring diabetes and to continue the significant progress we have made in the past year. ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement. Moving forward, we are optimizing the effectiveness of both PEC-Direct and PEC-Encap, the latter of which incorporates novel device material technology created in collaboration with W.L. Gore & Associates. We are also making important progress on our PEC-QT program with our partner, CRISPR Therapeutics, and are now moving into pre-IND activities. This program is designed to eliminate the need for immuno-suppression and could have a transformative impact on a broader population of insulin-dependent patients."

Dr. Laikind continued, "In conjunction with the closure of the financing, we are also pleased to announce the appointment of Ian F. Smith as our Executive Chairperson, succeeding Fred Middleton. Since joining the board last July, Ian and I have worked closely to accelerate ViaCyte's growth and prepare for the future. We are extremely grateful to Fred for his many years of service as Chairperson of ViaCyte's Board of Directors. Throughout his time leading the Board, Fred provided expert guidance as ViaCyte has consistently broken new ground in the field of regenerative medicine and cell replacement therapies."

Mr. Middleton said, "I am proud to have chaired the Board as ViaCyte developed into a leading company in the regenerative medicine field.I am confident that Ian's unique expertise and executive leadership, specifically with innovative growth-oriented companies, and specifically in corporate strategy and operations, as well as capital markets will help ViaCyte progress its important work and firmly establish itself as a leader in the cell therapy sector."

About ViaCyte's Pipeline

The PEC-Direct product candidate, currently being evaluated in the clinic, delivers ViaCyte's PEC-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. The PEC-Encap (also known as VC-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. PEC-Encap is being developed for all patients with type 1 diabetes. In collaboration with CRISPR Therapeutics, ViaCyte is developing immune-evasive stem cell lines from its proprietary CyT49 cell line. These immune-evasive stem cell lines, which are being used in the PEC-QT program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. In addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

About ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte's product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. Over a decade ago, ViaCyte scientists were the first to report on the production of pancreatic cells from a stem cell starting point and the first to demonstrate in an animal model of diabetes that, once implanted and matured, these cells secrete insulin and other pancreatic hormones in response to blood glucose levels and can be curative. More recently, ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. The Company also has a robust intellectual property portfolio, which includes hundreds of issued patents and pending applications worldwide. ViaCyte is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. For more information on ViaCyte, please visit http://www.viacyte.comand connect with ViaCyte on Twitter, Facebook, and LinkedIn.

View original content to download multimedia:http://www.prnewswire.com/news-releases/viacyte-announces-27-million-financing-to-advance-next-generation-cell-therapies-for-diabetes-301063742.html

SOURCE ViaCyte, Inc.

See the original post:
ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes - BioSpace

MarketsandResearch.biz has released a new research report titled Global Regenerative Medicine Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2026 to its database which presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis, and key drivers. The report encompasses all the prime factors, making this report extremely useful to all the entrants and potential investors in the global Regenerative Medicine market. The data simplifies this study using a series of channels, including data ranging from rudimentary data to meticulously drawn estimates. Key drivers, as well as challenges of the market, are discussed in the report. The report provides an in-depth analysis of the market with current and future trends.

The report further talks about the definition, types, applications, and major players of the Regenerative Medicine market in detail. The report offers thorough knowledge about the opportunities in business, market status& forecast, the possibility of generating revenue, regional market by different end-users as well as types and future forecasts of upcoming years. The report looks at market status (2015-2020), competitive scenario, advantages and disadvantages of different products and different market players, industry development trends and insights (2020-2026), and regional dominant participants.

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/44907

Below mentioned is the list of few companies engaged in the market: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of product types of market: Mono Avalanche Airbags, Dual Avalanche Airbags

The study explores the key applications/end-users of the market: Skiing, Climbing, Hiking, Others

Furthermore, the report includes a deep compilation of the respective industry and a detailed overview of its segmentation. The report offers a fundamental outlook of the global Regenerative Medicine markets present status and size in terms of volume and value. The essential data about the vital geographical regions and primitive players has been summarized in the report. The market has been broken down into various segments, regions, end-uses, and players to provide a clear picture of the present market situation. Segmentation of the market highlights the growth prospects and trends impacting these segments.

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/44907/global-regenerative-medicine-market-2020-by-manufacturers-regions-type-and-application-forecast-to-2026

The Geographical Landscape of The Market:

The research offers an analysis of the geographical landscape of the global Regenerative Medicine market, which is divided into regions such as North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa). It includes data about several parameters related to the regional contribution. The study provides information regarding the sales generated through each region and the registered market share. Information related to the growth rate during the forecast period is included in the report. According to the report, the industry is projected to generate significant revenue during the forecast period.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

View original post here:
Global Regenerative Medicine Market Research Report With COVID-19 Update - Cole of Duty

OXFORD, England, May 27, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce the appointment of Martin Andrews as a Non-Executive Director. Martin is a highly experienced senior pharmaceutical executive with broad R&D, commercial and operational experience, and has deep specialist expertise in rare diseases, gene therapy and vaccines.

Martin is an experienced Non-Executive Director and commercial leader, with a strong track record of strategy development and operational delivery. He has had a long and successful career at GlaxoSmithKline, where he has held many senior positions. Most recently, Martin was Senior Vice President, Rare Diseases. Here, he led the global rare disease business and oversaw the development of a portfolio of ex vivo gene therapies, and the launch of Strimvelis, the world's first life-saving gene therapy for children. Furthermore, under his leadership, GlaxoSmithKline transferred its gene therapy portfolio to Orchard Therapeutics. Prior to that, Martin was Senior Vice President, Global Vaccines Commercial, where he led the development of the growth strategy and transformation of the commercial capability in GlaxoSmithKline's Vaccines division.

Martin has previously held Board positions at Orchard Therapeutics and the Alliance for Regenerative Medicine. He is currently a Non-Executive Director of Freeline Therapeutics, where he brings his commercial expertise to their gene therapy portfolio of drugs.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented:

"We're very pleased to welcome Martin as a Non-Executive Director. With his rare disease drug development experience and strong track-record of commercial success, Martin will be a great asset to the company. His expertise will play an important role in helping guide our business growth."

Commenting on his appointment, Martin Andrews said:

"I'm delighted to be joining the Board of Evox.This is an exciting period for the Company and I believe its technology has the potential to transform how medicines are developed and delivered for patients with conditions that are not possible to treat adequately today, especially those with rare diseases. I am thrilled to be part of the team and look forward to contributing."

About Evox Therapeutics

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading life sciences venture capital groups and supported by a comprehensive intellectual property portfolio, Evox's mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families. Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies, and Evox is leading the development within this emerging therapeutic space.

For further information visit: http://www.evoxtherapeutics.com

View original content:http://www.prnewswire.com/news-releases/evox-therapeutics-appoints-martin-andrews-as-non-executive-director-301065071.html

SOURCE Evox Therapeutics

Read the original post:
Evox Therapeutics Appoints Martin Andrews as Non-Executive Director - P&T Community

Global Regenerative Medicine Market Size, Status And Forecast 2020-2026: It offers detailed research and analysis of key aspects of the global Regenerative Medicine market. This report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Regenerative Medicine market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Regenerative Medicine market is carefully analyzed and researched about by the market analysts.

The global regenerative medicine market size was USD 23,841.5 Million in 2018 and is Projected to Reach USD 151,949.5 Million by 2026

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/Regenerative Medicine players in the market. Top Companies in the Global Regenerative Medicine Market: Acelity, DePuy Synthes, Medtronic, Zimmer Biomet, Stryker, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori Therapeutics, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologes, Bellicum Pharmaceuticals.and Others.

(Special Offer: Available Flat 30% Discount for a limited time only):

Click Here ToGet Sample Copy of the Report:https://www.marketinsightsreports.com/reports/01311075193/global-regenerative-medicine-market-size-status-and-forecast-2019-2025/inquiry?source=bestresearchreports&Mode=54

This report segments the Global Regenerative Medicine Market on the basis of Types are:

Cell Therapy

Tissue Engineering

Biomaterial

On the basis of Application, the Global Regenerative Medicine Market is segmented into:

DermatologyCardiovascularCNSOrthopedic

Regenerative Medicine Market Outlook:

The oncology segment is likely to augment at the fastest CAGR over 2019-2025 due to the increasing number cancer patients across the globe, and a growing number of clinical trials in oncology indications. Approx. 53% of all current clinical trials are in oncology, such as lymphoma, leukemia, and cancer of breast, colon, brain, pancreas, cervix, bladder, and esophagus, among others.

KEY INDUSTRY DEVELOPMENTS

In 2018, Novartis received EU approval for one-time gene therapy Luxturna, which has been developed to restore vision in people with rare and genetically-associated retinal disease.

In 2018, Novartis received EU approval for its CAR-T cell therapy, Kymriah.

In 2017, Integra LifeSciences launched its product, Integra Dermal Regeneration Template Single Layer Thin for dermal repair defects reconstruction in a one-step procedure.

Browse The Full Report Description and TOC:https://www.marketinsightsreports.com/reports/01311075193/global-regenerative-medicine-market-size-status-and-forecast-2019-2025?source=bestresearchreports&Mode=54

Important Features that are under Offering and Regenerative Medicine Highlights of the Reports:

Detailed overview of Market

This report provides pin-point analysis for changing competitive dynamics.

In-depth market segmentation by Type, Application etc

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Regenerative Medicine Market

Strategies of Regenerative Medicine players and product offerings

Potential and niche segments/regions exhibiting promising growth

Finally, Regenerative Medicine Market report is the believable source for gaining the Market research that will exponentially accelerate your business. The report gives the principle locale, economic situations with the item value, benefit, limit, generation, supply, request and Market development rate and figure and so on. This report additionally Present new task SWOT examination, speculation attainability investigation, and venture return investigation.

We also offer customization on reports based on specific client requirement:

Browse More Related Reports;

Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Professional Survey Report 2019

https://www.marketinsightsreports.com/reports/11261589875/global-paroxysmal-nocturnal-hemoglobinuria-treatment-market-professional-survey-report-2019?mode=54

Global Cell Expansion Technologies Market Insights, Forecast To 2025

https://www.marketinsightsreports.com/reports/12261036386/global-cell-expansion-technologies-market-insights-forecast-to-2025?mode=54

Global Stem Cell Assay Market Size, Status And Forecast 2019-2025

https://www.marketinsightsreports.com/reports/06251316704/global-stem-cell-assay-market-size-status-and-forecast-2019-2025?mode=54

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

About Us:

MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, Regenerative Medicine trends, and strategic recommendations.

Contact Us:

IrfanTamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected]| [emailprotected]

Read more:
Regenerative Medicine Market In-deep Analysis And Experts Review Report 2020-2026 - Cole of Duty

Mike Tyson has attributed his incredible body transformation to stem cell therapy and a rigid vegan diet.

The youngest world heavyweight champion in history ballooned to more than 300lbs in weight at his heaviest almost a decade ago.

However, after drastically changing his diet and implementing revolutionary reparative medication, Iron Mike is looking more streamlined and more devastating than ever.

Tyson is reportedly considering making a return to the squared circle at the age of 53, with an announcement on his opponent expected this week.

Whilst training with UFC legends Vitor Belfort and Henry Cejudo, the former undisputed heavyweight champion displayed a significantly more shredded physique.

Prior to officially announcing his desire to return, Tyson was asked by rapper LL Cool J how he would get fighting fit in just six to eight weeks.

He told Rock the Bells Radio show on SiriusXM: Really I would just change my diet and just do cardio work. Cardio has to start, you have to have your endurance to go and do the process of training.

Mike Tyson

So something to do is get in cardio, I would try and get two hours of cardio a day, make sure you get that stuff in. Youre gonna make sure youre eating the right food.

For me its almost like slave food. Doing what you hate to do but doing it like its nothing. Getting up when you dont want to get up. Thats what it is. Its becoming a slave to life.

People think a slave to life is just enjoying drugs and living your life. Being a slave to life means being the best person you can be, being the best you can possibly be, and when you are at the best you can possibly be is when you no longer exist and nobody talks about you. Thats when youre at your best.

Tyson continued: My mind wouldnt belong to me. My mind would belong to somebody that disliked me enough to break my soul, and I would give them my mind for that period of time.

Six weeks of this and Id be in the best shape Ive ever dreamed of being in. As a matter of fact, Im going through that process right now. And you know what else I did, I did stem-cell research.

Stem-cell research (also known as regenerative medicine) promotes the repair response of diseased, dysfunctional or injured tissue using stem cells or their derivatives.

It is the latest advancement in organ transplantation and uses cells instead of donor organs, which are limited in supply.

After LL Cool J asked if that meant Tysons white blood cells had been spun and then put back in, Tyson continued: Yes. As they took the blood it was red and when it came back it was almost transfluid [sic], I could almost see through the blood, and then they injected it in me. And Ive been weird ever since, Ive got to get balanced now.

Getty Images - Getty

The necessity to repair the former heavyweight champion was caused by the excessive weight gain following his retirement in 2005 and his hedonistic lifestyle.

Excessive cocaine abuse left the heavyweight in a serious state of bother and led him to adopt a vegan lifestyle.

He told Totally Vegan Buzz: I was so congested from all the drugs and bad cocaine, I could hardly breathe. Tyson also revealed in the interview, I had high blood pressure, was almost dying, and had arthritis.

During aninterviewwith Oprah Winfrey in 2013, Tysoncredits his plant-based diet for saving his life.

Getty Images

He said: Well, my life is different today because I have stability in my life. Im not on drugs.

Im not out on the streets or in clubs and everything in my life that I do now is structured around the development of my life and my family. I lost weight.

I dropped over 100lbs and I just felt like changing my life, doing something different and I became a vegan.

Read this article:
Vegan diet, intense cardio and stem cell therapy How Mike Tyson managed to get ripped at 53 as boxing c - talkSPORT.com

PONTE VEDRA BEACH, Fla., May 26, 2020 /PRNewswire/ --Throughout the pandemic, ventilator support has been in short supply. And for one family in Ecuador, finding a ventilator and getting it flown to the small hospital where their one-year-old son was being treated for a rare neuromuscular disorder seemed an insurmountable task.

But worlds away, two organizations on different continents used their network to not only find one, but get it donated and shipped in the nick of time all through families connected by the same thread -- having children affected by centronuclear and myotubular myopathy disorder.

One-month-old Wilson is now stable and ready to go home in Ecuador thanks the herculean efforts of Florida-based Joshua Frase Foundation and Zusammen Stark! eV (CNM-Together Strong), an association in Germany.

"The families that played a role in giving mechanical breath to this child know all too well the priceless value it holds, especially in that fragile first year with a child diagnosed with a nueromuscular disorder. "Having been through it ourselves, we know that without it, this child would pass," said Alison Rockett Frase, founder of Joshua Frase Foundation.

Wilson, like Alison's late son Joshua for whom the foundation is named, was born with myotubular myopathy, which causes very weak muscles, the patient is unable to eat without a feeding tube and requires a ventilator to breathe.

In Ecuador, the healthcare system cannot provide a portable ventilator for parents to take their child home to live out their life. "That means that his family can either chose to keep him alive and institutionalized or bring him home to perish unless they can find a way to pay for or acquire a home ventilator on their own," explained Frase.

Desperate to bring Wilson home, his family reached out to CNM Together Strong!, the association that helps families with centronuclear myopathies in Germany. They connected with Alison and the Joshua Frase Foundation, known for managing a medical equipment exchange program in the U.S.

"The logistical challenges from one country to the next, from customs and language barriers, to the updating of obsolete equipment were all overcome to save Wilson's life," said Frase. "This story shows that the beauty of humanity knows no boundaries and can span three continents, even when the world has been turned upside down."

For Wilson's parents, the gift was more than just a medical machine. "This was not just a gift of breath, but a gift of life in the truest sense," said Andre Carlozama and Daniel Augalsaca. "The joy and elation of now being able to bring Wilson home is immeasurable."

Both the Joshua Frase Foundation and CNM-Together Strong! in Germany are hoping to help the family with additional medical expenses, including maintenance of the ventilator and for doctor care while he is at home. For donations, please visit http://www.pleasedonate.organd tag "for Willson".

"Although children born with this often-fatal disorder live on borrowed time, it is essential that every family be provided the opportunity to bring their child home to spend quality time outside institutional walls," said Frase. "Every donation will mean so much for this family."

About The Joshua Frase Foundation(JFF) is a 501C3 non-profit organization that was founded in 1996; a year after Paul and Alison's son was born with an ultra rare and fatal neuromuscular disorder. Without hesitation, the foundation began funding cutting-edge research in the area of regenerative medicine, gene therapy and genetics since 1997. JFF's mission is twofold: To find a cure or treatment for centronuclear and myotubular myopathies and to support families whose lives are affected by these disorders. Not only has JFF been able to fund groundbreaking science, pioneering into a curative treatment that has the potential to transform neuromuscular research; it has also built an international community of children and their parents. The foundation's efforts have spearheaded human clinical trials for gene therapy. For more information, please visit http://www.joshuafrase.org.

About ZNM Zusammen Stark! e.V.(CNM Together Strong!) is a self-help association for myotubular myopathy and other centronuclear myopathies (CNM = ZNM). We represent (as of October 2019) 159 individuals from 52 families with a CNM in Germany, the Netherlands and Austria. As a self-help organization our main goal is to connect those affected and their families and to support each other in our daily lives. This is mainly done by our yearly family conference, conference, webinars and our closed Facebook support group. We also actively invest on research to find a treatment for these conditions. For more information please visit https://www.znm-zusammenstark.org/en.

Media Contacts: Alison Rockett Frase, Joshua Frase Foundation904-567-3933 or [emailprotected]Liz Morgan, Liz Morgan PR 904-608-3823 or [emailprotected]

SOURCE Joshua Frase Foundation

http://www.joshuafrase.org

Read the original here:
Amid COVID 19 Crisis, Joshua Frase Foundation Leads Search Spanning Two Continents to Deliver Ventilator to Ailing Child in Ecuador - PRNewswire

ZUG, Switzerland and CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in June:

Jefferies Global Healthcare ConferenceDate:Tuesday, June 2, 2020Fireside chat: 1:30 p.m. ET

Goldman Sachs 41st Annual Global Healthcare ConferenceDate:Tuesday, June 9, 2020Fireside chat: 9:40 a.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website athttps://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1 617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel EidesWCG on behalf of CRISPR+1 617-337-4167reides@wcgworld.com

The rest is here:
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Global Regenerative Medicine Market Added by Report Ocean covers valuable insights based on market valuation, market size, SWOT Analysis, revenue forecast and regional outlook of this industry. The research also presents a precise summary of the industry competitive spectrum, while drawing attention to the growth prospects and expansion plans adopted by key market players.

The global regenerative medicine market report is a comprehensive research study of this business space that has been projected to garner highly appreciable returns by the end of the forecast duration. The report analyzes global regenerative medicine market and provides an insight into pivotal parameters such as market size, sales volume, revenue forecast. The segmentation of the global regenerative medicine market and intrinsic details regarding these segments in addition to the specific drivers fueling the remuneration and commercialization landscape of this business space have also been enumerated in this report.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=43390

In this report, we analyze the Global Regenerative Medicine Market from two aspects.

1. Production In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019.

2. Consumption In terms of consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019.

We also make a prediction of its production and consumption in coming 2020-2026.

At the same time, we classify different regenerative medicine market based on their definitions. Upstream raw materials, equipment and downstream consumers analysis is also carried out. It also focuses on market influencing factors, competitive landscape, data, trends, information, and exclusive vital statistics of the market.

A brief summary of how the regenerative medicine market will perform has been illustrated in the report. Moreover, crucial specifics such as growth drivers as well as the expected growth rate of the regenerative medicine market during the forecast period are included in the report. The report also details the potential growth aspects along with the restraints of this industry vertical.

Global Regenerative Medicine Market report focuses on various key parameters that include:

Market concentration ratio

Consumption growth rate

Growth rate

Turnover predictions

Industry drivers and major challenges

Recent market trends

Geographical segmentation

Competitive structure

Competitive ranking analysis

Competitive Landscape:

The competitive analysis of major market players is another notable feature of the regenerative medicine market report; it identifies direct or indirect competitors in the market.

Key parameters which define the competitive landscape of the Global Regenerative Medicine Market:

Profit margins

Product sales

Company profile

Product pricing models

Sales geographies

Distribution channels

Industry evaluation for the market contenders

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of regenerative medicine market. The common characters are also being considered for segmentation such as global market share, common interests, worldwide demand and supply of Access Control devices. Moreover, the report compares the production value and growth rate of regenerative medicine market across different geographies.

Unravelling the geographical landscape of the Global Regenerative Medicine Market:

Americas (United States, Canada, Mexico, Brazil)

APAC (China, Japan, Korea, Southeast Asia, India, Australia)

Europe (Germany, France, UK, Italy, Russia, Spain)

Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

The research methodology adopted by analysts to study the market include inputs derived from industry professionals across the value chain and various other secondary research methods, along with primary research as a major tool for market study.

Some of the Major Highlights of TOC covers:

Executive Summary

Global Regenerative Medicine Market Insights

Global Regenerative Medicine Market forecast by different Segments and Regions

Manufacturing Cost Structure Analysis

Development and Manufacturing Plants Analysis of regenerative medicine market

Key Figures of Major Manufacturers

Development Trend of Analysis of regenerative medicine market

Global Regenerative Medicine Market Trend Analysis

Global Regenerative Medicine Market Size (Volume and Value) Forecast 2020-2026

Marketing Channel

Direct Marketing

Indirect Marketing

Global Regenerative Medicine Market Customers

Market Dynamics

Market Trends

Opportunities

Market Drivers

Challenges

Influence Factors

Methodology/Research Approach

Research Programs/Design

Market Size Estimation

Market Breakdown and Data Triangulation

Data Source

Key Questions Addressed in the Report:

1. Who are the top 10 players operating in the regenerative medicine market?

2. What are the driving factors, restraints, opportunities, and challenges in the regenerative medicine market?

3. What are the current scenario and industry trends in the regenerative medicine market?

4. Which industry and technology can be a potential revenue pocket for market players in the next five years?

5. Who are the visionary leaders, dynamic differentiators, innovators, and emerging players and what are the key strategies adopted by them to strengthen their positions?

6. What are the regenerative medicine market opportunities and threats faced by the vendors in the regenerative medicine market?

7. What are the regenerative medicine market challenges to market growth?

8. Analysis based on historical information along with the current trends to estimate the future of the market

9. Analysis of the impact of constantly changing global market scenarios

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=43390

Note: The report historic years and forecast period can be customized on the request. Moreover, the scope of a published report can be modified as per the requirement, specific geography or country-based analysis can be provided as a part of customization

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Nick MartinEmail:[emailprotected]

Read this article:
Global Regenerative Medicine Market Industry Analysis and Forecast (2019-2026) by Product type, Application and Region Cole Reports - Cole of Duty

The global Regenerative Medicine market offers a thorough study of all the important aspects of the market. All the factors that are responsible for the growth of the global market are studied in this report. In addition to that, the factors causing hurdles in the path are also studied in the report. For the study of any market it is very important to study some factors such as market trends, revenue growth patterns market shares, demand and supply. In addition, it also covers political and social factors which is likely to affect the growth of the market. Production, market share, revenue rate, key regions and major vendors are some of the vital aspects analysed in the report. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users.

Get sample copy of Regenerative Medicine Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/52

The global Regenerative Medicine market is a detailed research report which covers all the quantitative as well as qualitative aspects about the Regenerative Medicine markets across the globe. The report is also inclusive of different market segmentation, business models and market forecasts. This market analysis enables the manufacturers with impending market trends. A thorough scrutiny of prominent market players or industrialists are vital aspect for planning a business in the market. Also, study about the rivals enables in attaining valuable data about the strategies, companys models for business, revenue growth as well as statistics for the individuals attracted towards the market. This report is very useful for the new entrants as it offers them with the idea about the different approaches towards the market.

Full Browse the report description and TOC: https://www.adroitmarketresearch.com/industry-reports/regenerative-medicine-market

There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Moreover, the report provides historical information with future forecast over the forecast period. Some of the important aspects analysed in the report includes market share, production, key regions, revenue rate as well as key players. This Regenerative Medicine market report also provides the readers with detailed figures at which the Regenerative Medicine market was valued in the historical year and its expected growth in upcoming years. This report on Regenerative Medicine market has been made in order to provide deep and simplified understanding of the market to its end users. In addition, the report include deep dive analysis of the market, which is one of the most important features of the market.

In addition, the market research industry delivers the detailed analysis of the global Regenerative Medicine market for the estimated forecast period. The market research study delivers deep insights about the different market segments based on the end-use, types and geography. One of the most crucial feature of any report is its geographical segmentation of the market that consists of all the key regions. This section majorly focuses over several developments taking place in the region including substantial development and how are these developments affecting the market. Regional analysis provides a thorough knowledge about the opportunities in business, market status & forecast, possibility of generating revenue, regional market by different end users as well as types and future forecast of upcoming years.

The company profiles also covers the detailed description and segmentation of the companies along the finances which are being covered for the company. The global Regenerative Medicine market is likely to provide insights for the major strategies which is also estimated to have an impact on the overall growth of the market. Several strategies such as the PESTEL analysis and SWOT analysis is also being covered for the global market. These strategies have an impact on the overall market. Furthermore, several factors such as the emergence of new opportunities is also likely to boost the growth of the market. In addition, the market research provides several detailed analysis for the market which has an impact for the end user.

For Any Query on the Regenerative Medicine Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/52

About Us :

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX75204, U.S.A.Phone No.: USA: +1 972-362 -8199/ +91 9665341414

View original post here:
Regenerative Medicine Market Analysis by Demand, Applications, End Users, Companies, Sales Prospects, Forthcoming Developments, Business Opportunities...

Dr. Timothy Chan, an immuno-oncology and cancer genomics expert, has been named director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic, according to a news release.

He will lead the new center, which brings together multidisciplinary experts from across the system to advance research and treatment related to immuno-oncology, a rapidly growing field.

"Immunotherapy is the future of research in cancer and various other diseases and Cleveland Clinic has made it a priority by establishing this new center," Dr. Serpil Erzurum, chair of the Clinic's Lerner Research Institute, said in a prepared statement. "The Center for Immunotherapy and Precision Immuno-Oncology will empower clinicians and scientists throughout the enterprise to advance personalized cancer care and breakthrough immunotherapy research at Cleveland Clinic."

The center, which opened this month with the arrival of Chan, was approved in 2019.

Chan joins the system from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he led the Immunogenomics and Precision Oncology Platform and was a tenured professor, the PaineWebber Chair and the Translational Oncology Division chair, according to the release, which notes he is a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies. He also joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University and is on staff in the Genomic Medicine Institute of the Lerner Research Institute and the Department of Radiation Oncology of the Taussig Cancer Institute, according to the release.

The Center for Immunotherapy and Precision Immuno-Oncology will have four arms: a Cleveland cell therapy program in collaboration with the Case Comprehensive Cancer Center; immunologic medicine and immuno-oncology labs; a precision immuno-oncology program; and a precision immuno-oncology and developmental therapeutics program.

The center will recruit experts from around the country and globe who specialize in computational science, immunotherapy and cancer immunology, according to the release.

Initially, the new center will have sites focused on immunotherapy research and developmental therapeutics in both Cleveland and the Cleveland Clinic Florida Research and Innovation Center, a 107,000-square-foot laboratory and office space slated to open this summer in Port St. Lucie, Fla. Chan will also collaborate with experts in the new Center for Global and Emerging Pathogens, which was announced last week after a year and a half of planning. This center looks to broaden the understanding of emerging pathogens (from Zika virus to SARS-CoV-2, which causes COVID-19) and expedite critically needed treatments and vaccines.

"Innovation in precision immunotherapy is one of the most exciting areas in cancer research," said Dr. Brian Bolwell, chairman of Taussig Cancer Institute, Cleveland Clinic Cancer Center, in a prepared statement. "The addition of Dr. Chan, a pioneer in cancer genomics, and the new center's focus on research and clinical trials will strengthen our ability to provide advanced treatment options for our patients."

Board certified in radiation oncology and an elected member of the Association of American Physicians, Chan earned his M.D. and Ph.D. in genetics from Johns Hopkins University, where he completed his residency in radiation oncology and a postdoctoral fellowship in the division of tumor biology, according to the release. He has published more than 200 articles in peer-reviewed journals, has made landmark discoveries in his field and has received numerous awards, including the National Cancer Institute Outstanding Investigator Award in 2018, according to the release.

Read more:
Dr. Timothy Chan to lead Cleveland Clinic's new Center for Immunotherapy and Precision Immuno-Oncology - Crain's Cleveland Business

Recently, the Federal service for supervision in the sphere of health issued the first Russian license for the production of biomedical cell products. She became the owner of a domestic biotechnology company Generium. This will make a significant breakthrough in the field of regenerative medicine.Regenerative medicine is one of the most rapidly growing industries. Its main task is to replace and restore the function of diseased organs or tissues in cases when the natural regenerative capacity of the organism is not able to ensure the restoration and healing of the defect.Methods of regenerative medicine directed on treatment of severe socially significant diseases with high levels of disability, as well as to fill therapeutic niches with high unmet needs.Cellular technology is the most advanced tool of personalized medicine. The presence of a unique infrastructure of Russian biotechnological enterprises making them the center of attraction for the representatives of international pharmaceutical industry and scientists from various fields of science (medics, biologists, physicists, engineers, chemists, IT specialists, mathematicians), and also allows to solve the most challenging public tasks in the field of health. Industrial tissue engineering becomes a reality, said the first Deputy Minister of industry and trade of the Russian Federation Sergey Tsyb.The main segments of the market for regenerative medicine products are tissue therapy and cell therapy biomedical cellular products, which is a cultured human cells. These lines are a driver in research activities of Russian and foreign research centers, which brings together scientists and clinicians around the world.Under the current license it is planned to develop and produce a unique range of autologous, allogeneic and combined BMK, and personalized therapy and diagnostics. Regenerative medicine is not a new technology in medicine and the other medicine. Developing methods for the modification of the cells and edit their genome. There is the prospect of a new therapy, which will focus not only on the regulation of living cells, but also to grow new cells, tissues, structures in our body. With the advent of the first industrial license we understand that regenerative medicine has the potential to become a new efficient branch of the Russian medicine for the treatment of the most severe human diseases incurable by other means, concluded the Dean of the faculty of fundamental medicine of Moscow state University. Lomonosov, academician of RAS AllLod Tkachuk.The world of biotechnology in the field of regenerative medicine are at the stage of explosive growth and investment. A persons ability to manage intra and extracellular processes helps us to create technologies to solve the most difficult tasks in the treatment of patients with serious illnesses or injuries. The countrys first license for industrial production of biomedical cell products gives Russia the opportunity to implement a number of sophisticated cutting edge projects, including to combat coronavirus infection. The country began the era of cellular technologies, said Professor, General Director of JSC GENERIUM Dmitry Kudlay.

More:
Breakthrough in regenerative medicine. Biomedical cell products in Russia - The KXAN 36 News

Like power lines in an electrical grid, long wiry projections that grow outward from neurons -- structures known as axons -- form interconnected communication networks that run from the brain to all parts of the body. But unlike an outage in a power line, which can be fixed, a break in an axon is permanent. Each year thousands of patients confront this reality, facing life-long losses in sensation and motor function from spinal cord injury and related conditions in which axons are badly damaged or severed.

New research by scientists at the Lewis Katz School of Medicine Temple University (LKSOM) shows, however, that gains in functional recovery from these injuries may be possible, thanks to a molecule known as Lin28, which regulates cell growth. In a study published online in the journal Molecular Therapy, the Temple researchers describe the ability of Lin28 -- when expressed above its usual levels -- to fuel axon regrowth in mice with spinal cord injury or optic nerve injury, enabling repair of the body's communication grid.

"Our findings show that Lin28 is a major regulator of axon regeneration and a promising therapeutic target for central nervous system injuries," explained Shuxin Li, MD, PhD, Professor of Anatomy and Cell Biology and in the Shriners Hospitals Pediatric Research Center at the Lewis Katz School of Medicine at Temple University and senior investigator on the new study. The research is the first to demonstrate the regenerative ability of Lin28 upregulation in the injured spinal cord of animals.

"We became interested in Lin28 as a target for neuron regeneration because it acts as a gatekeeper of stem cell activity," said Dr. Li. "It controls the switch that maintains stem cells or allows them to differentiate and potentially contribute to activities such as axon regeneration."

To explore the effects of Lin28 on axon regrowth, Dr. Li and colleagues developed a mouse model in which animals expressed extra Lin28 in some of their tissues. When full-grown, the animals were divided into groups that sustained spinal cord injury or injury to the optic nerve tracts that connect to the retina in the eye.

Another set of adult mice, with normal Lin28 expression and similar injuries, were given injections of a viral vector (a type of carrier) for Lin28 to examine the molecule's direct effects on tissue repair.

Extra Lin28 stimulated long-distance axon regeneration in all instances, though the most dramatic effects were observed following post-injury injection of Lin28. In mice with spinal cord injury, Lin28 injection resulted in the growth of axons to more than three millimeters beyond the area of axon damage, while in animals with optic nerve injury, axons regrew the entire length of the optic nerve tract. Evaluation of walking and sensory abilities after Lin28 treatment revealed significant improvements in coordination and sensation.

"We observed a lot of axon regrowth, which could be very significant clinically, since there currently are no regenerative treatments for spinal cord injury or optic nerve injury," Dr. Li explained.

One of his goals in the near-term is to identify a safe and effective means of getting Lin28 to injured tissues in human patients. To do so, his team of researchers will need to develop a vector, or carrier system for Lin28, that can be injected systemically and then hone in on injured axons to deliver the therapy directly to multiple populations of damaged neurons.

Dr. Li further wants to decipher the molecular details of the Lin28 signaling pathway. "Lin28 associates closely with other growth signaling molecules, and we suspect it uses multiple pathways to regulate cell growth," he explained. These other molecules could potentially be packaged along with Lin28 to aid neuron repair.

Reference:

Fatima M. Nathan, Yosuke Ohtake, Shuo Wang, Xinpei Jiang, Armin Sami, Hua Guo, Feng-Quan Zhou, Shuxin Li. Upregulating Lin28a Promotes Axon Regeneration in Adult Mice with Optic Nerve and Spinal Cord Injury. Molecular Therapy, 2020; DOI: 10.1016/j.ymthe.2020.04.010

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
Scientists Regenerate Neurons in Mice with Spinal Cord Injury and Optic Nerve Damage - Technology Networks

Last week, we published a briefing that flip-flopped between bad news and good(ish) news. Were balancing todays briefing in a similar vein, tempering the more negative with the more hopeful.

Todays Coronavirus Briefing is 1,078 words and will take you five minutes to read.Click here to sign up for the newsletter.

Bad. Good. Hopeful. Scary. Thank you. Very sad.

Sponsored content

With the COVID-19 outbreak causing an unprecedented impact on the Healthcare Marketing Industry, non-personal promotion has never been more critical. As HCPs are facing this crisis on both professional personal fronts, supporting them through the delivery of your key messaging will be important to the continued care of patients with existing illnesses and chronic conditions.

This is all good, and aspirational news.

Fingers crossed we get to report positively about all of the above, in the coming weeks.

A range of views of our various futures: revolutionary, hopeful, dark and progressive.

A Magic 8-Ball seems like as plausible a barometer for whats to come as anything, or anyone else these days.

Lately, for every Instagram post of someones elaborate meal is an outdoor post of their new-found gardening skills.

If the virus returns this winter, were all going to have to learn vertical indoor farming.

A brief rabbit hole of workplace nostalgia.

See you tomorrow in shoulder pads and feathered hair in quarantine no ones around to see...

Follow this link:
Coronavirus Briefing: Medical breakthroughs, the future of PR, gardens and workplace nostalgia - PRWeek

Its still not clear whether Gov. Kate Brown will allow some beauty treatments to resume as part of her decision to allow medical offices to restart elective procedures as early as Friday after more than a monthlong shutdown to stem the spread of the novel coronavirus.

After several days of questioning from The Oregonian/OregonLive, the governors office said Brown didnt intend to allow aesthetician services, medical spas, facial spas, and non-medical massage services to reopen.

But how about doctors or nurse practitioners who provide medical beauty services such as wrinkle reduction?

Spokeswoman Liz Merah said to stay tuned. The state might have additional guidance on opening day, she said.

In a sampling by The Oregonian/OregonLive, some owners believed they werent allowed to reopen, while others were adamant that the governor had given their industry permission to restart anti-aging or aesthetic procedures meant to improve the appearance of the skin or body.

Neighboring governors also have announced the loosening of some restrictions on the medical industry, albeit on a more limited basis than in Oregon.

California Gov. Gavin Newsom said last week that some elective or delayed surgeries -- such as those for cancer or heart problems -- can resume. But Newsom specified cosmetic surgeries are still barred for the time being.

Washingtons Gov. Jay Inslee on Wednesday clarified a previous order restricting nonurgent procedures. He gave health care providers more leeway to resume some of the procedures if delaying them would significantly harm the patient. Inslees direction appears to offer no wiggle room for Botox businesses or other medical spas to reopen.

The confusion in Oregon arose when Brown announced last week that elective, non-urgent medical and dental procedures could restart but didnt offer a specific list of businesses.

She and Dr. Dana Hargunani, the Oregon Health Authoritys chief medical officer, cited examples instead -- including knee surgeries, fertility treatments, dental cleanings, cancer biopsies and hip replacements.

When a reporter asked Hargunani whether cosmetic procedures would be allowed, Hargunani didnt answer directly yes or no. Instead, she left the door open, saying: We are not telling providers exactly what they can or cannot do. But we know that those that are most urgent and necessary are going to be the first on the list.

That might have looked like a green light to many.

Aesthetic Medicine run by Dr. Jerry Darm -- one of the most recognizable faces in Oregons medical beauty industry -- announced his Lake Oswego office will start seeing customers again Monday.

We are reopening May 4th!!!!! Darms Facebook page reads. We are so excited to see our patients and have our staff back. There will be new guidelines for scheduling an appointment but we are feeling very blessed.

The post was met with a flurry of likes and comments such as Awesome!!!! I can wait to see you again and Thats so good to hear the good news.

Darm and the operators of several other medical beauty businesses contacted by the newsroom didnt return messages asking for details about safety protocols and the reason for their decisions to reopen. That includes Key Laser Institute for Cosmetic Regenerative Medicine in outer Southwest Portland, which posted on its Facebook page that its gearing up to see patients again.

Key Laser Institute for Cosmetic Regenerative Medicine's Facebook Post April 27, 2020. (Facebook screenshot)

Some others said its far too soon. Theyre concerned that meager testing means the state doesnt have a handle on the true scope of the problem or the knowledge needed to contain the virus spread through contact tracing.

While Oregon has by far a lower number of known cases and deaths than some other states -- 2,510 positive tests and 103 deaths it also has tested only about one in every 100 residents.

Coronavirus in Oregon: Latest news | Live map tracker |Text alerts | Newsletter

Debora Masten, a certified advanced esthetician in Salem, said she wont start offering customers chemical peels, laser hair removals and other treatments Friday because she doesnt think her services are necessary at this stage in the pandemic.

Its supposed to be stuff you cant put off, Masten said. Im anxious to get open again, too, but I think we have to try as best we can to protect the public.

Masten also noted that like many others who perform a range of treatments, shes not a doctor or nurse practitioner and the governor hasnt given her the OK. Thats even though she sees others who also arent medical professionals gearing up to reopen.

Sharon Griffin, a naturopathic doctor who operates Plush Botox Bar in Northeast Portland, wrote the governor this week urging her to end the confusion.

She asked Brown to specifically require the medical beauty industry to remain shuttered, like so many other businesses ranging from clothing stores to hair salons to dine-in restaurants.

No one really needs Botox in May, but as things stand, theyre gonna get it and possibly a whole lot more in the bargain, Griffin wrote.

She said in an interview that she supports restarting necessary procedures, like her husbands CT scan scheduled next week to diagnose a medical problem.

But she has decided to hold off reopening her own business until at least June 1 to see how the spread of the disease continues to play out, even as she sees competitors around her planning to reopen.

Griffin said shes passionate about what she does -- injectables such as Botox and lip fillers -- but doesnt want to risk the health of customers for procedures that arent life or death matters.

Nobody will die from a wrinkle, Griffin said.

-- Aimee Green; agreen@oregonian.com; @o_aimee

Subscribe to Oregonian/OregonLive newsletters and podcasts for the latest news and top stories.

Read this article:
Confusion reigns over whether Oregonians can receive Botox, other beauty treatments during the coronavirus pa - OregonLive

SAN DIEGO, May 1, 2020 /PRNewswire/ --SunevaMedical,Inc., is proud to announce an exciting new partnership that will further its leadership position in regenerative aesthetics. The exclusive North American distributorship for Sinclair Pharma's innovative Silhouette Instalift sutures will expand Suneva Medical's aesthetic portfolio that addresses the growing market demand for natural and minimally invasive alternatives in aesthetics.

"We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio," saysPat Altavilla, CEO, Suneva Medical. "These unique sutures fit perfectly as they can provide immediate lift to sagging cheeks and, like Bellafill, can activate the patient's natural collagen production over time."

"With Suneva Medical, we have a partnership with a company that has strong commercial presence in the U.S. while giving us the ability to expand our footprint in the North American market," says Chris Spooner, CEO Sinclair Pharma.

To learn more about Suneva Medical and upcoming news from the aesthetics company, please visitwww.SunevaMedical.com.

About Suneva Medical, Inc.Suneva Medical, Inc.headquartered inSan Diego, CAis a leader in regenerative aesthetics. It is focused on developing, manufacturing and commercializing branded products for providers and their patients. Suneva Medical offers a portfolio of best-in-class products that include Bellafill, the only FDA approved 5-year filler, Puregraft, a unique fat grafting system and Amplifine, an innovative high density platelet rich plasma (PRP) get tube.For more information, visitwww.sunevamedical.com.

About Sinclair PharmaSinclair Pharma is a fully owned subsidiary of Huadong Medicine Limited and headquartered in London, UK. The company operates in the fast growth, global aesthetics market and has built a strong portfolio of differentiated, complementary aesthetics technologies, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Group has an established sales and marketing presence in the leading EU markets, Brazil, Mexico, UAE and South Korea and a network of international distributors. For more information, visit http://www.sinclairpharma.com.

More:
Suneva Medical Increases Its Leadership in Regenerative Aesthetics with New Partnership - WFMZ Allentown

Mercy Plastic Surgery

1229 E. Seminole Suite 340, Springfield, MO |417-820-9330Theres a new member of the team at Mercy Plastic Surgery! Dr. Raghu Nandan is new to Springfield, but not to the operating room. Dr. Nandan is Board Eligible since completing his plastic surgery training at Johns Hopkins University in Baltimore after general surgery with the University of Arizona. Mercy was glad to welcome him in August of 2019.

Dr. Nandan offers head-to-toe care for his patients in Mercys high-quality medical facilitieshe specializes in breast reconstructions and augmentations, cosmetic injections, complex facial plastic surgery, scar revisions, tummy tucks and liposuction. He also assists in the care of breast cancer and melanoma patients.

When asked what he loves most about his work, Dr. Nandan says that he enjoys the opportunity to spend time with his patients, listening to their needs. He believes that by listening to patients, he can connect with them to better understand the best way to help them get the outcome they are looking for. Making positive changes in peoples lives, restoring their form and function and improving their quality of life gives him joy the fact that they can feel more confident is the best part of his career.

Tell us about a time you improved someones life, how you did it and how it felt.I had a teenage patient that was preparing for a leg amputation. Instead, we were able to restore the form and function of his leg. He later walked into the clinic and was showing off his soccer skills to the staff. Being a part of his care was priceless.

Why did you choose to go into your current profession?I chose to be a plastic surgeon to be able to restore form, function and aesthetics, from head to toe. It is one of the very few fields of medicine where you are able to innovate, push the envelope and markedly improve the quality of life and confidence of your patients.

Continue reading here:
Health These Springfield Experts Want to Help You Be Your Best Self When do you feel - 417mag

Doctors are hoping stem cell therapy could be a weapon in the fight against coronavirus. On Friday, regenerative medicine company Mesoblast announced a 300-person trial to determine whether stem cell treatments will work in COVID-19 patients suffering from severe lung inflammation.

One hospital in New York tried it as an experiment with 12 patients, 10 of whom were able to come off of ventilators.

"What we saw in the very first patient was that within four hours of getting the cells, a lot of her parameters started to get better," Dr. Karen Osman, who led the team at Mount Sinai, told CBS News' Adriana Diaz.

The doctor said she was encouraged by the results, though she was hesitant to link the stem cell procedure to her patients' recovery.

"We don't know" if the 10 people removed from ventilators would not have gotten had they not gotten the stem cells, she said. "And we would never dare to claim that it was related to the cells."

She explained that only a "randomized controlled trial" would be the only way "to make a true comparison."

Luis Naranjo, a 60-year-old COVID-19 survivor, was one of Mount Sinai's stem cell trial success stories. He told Diaz in Spanish that he was feeling "much better."

Naranjo's daughter, Paola, brought him to the emergency room, fearful she would not see her father again. Like so many families struck by the coronavirus, she was not allowed inside with him.

"I forgot to tell him that I love him," she said. "All I said was go inside, I hope you feel better."

During his hospital stay, Naranjo was unconscious and on a ventilator for 14 days.

Doctors proposed giving him stem cells from bone marrow in hopes it would suppress the severe lung inflammation caused by the virus.

Now, Naranjo credits the doctors who treated him for his survival. Though income from his family's jewelry business has been cut off and they found themselves falling behind on rent, Naranjo said he is focused primarily on his recovery and regaining the 25 pounds he lost at the hospital.

Although stem cell treatment, usually reserved for other diseases like rheumatoid arthritis, might end up being another step toward helping coronavirus patients recover, Dr. Osman was quick to say it would not be a "miracle treatment."

"The miracle treatment will be a vaccine," she said.

The rest is here:
Coronavirus Doctors experiment with stem cell therapy on COVID-19 patients CBS News 9:39 AM - KTVQ Billings News

In the search for improved and high-throughput in vitro models, organoids have emerged as a promising 3D cell culture technology.1 Defined as a three-dimensional multicellular in vitro tissue construct, organoids are derived from cells that spontaneously self-organize into properly differentiated functional cell types to mimic at least some function of an organ.2 Organoid formation is driven by signaling cues in the extracellular matrix and medium, and is influenced by the particular cell types that are present.2 Compared with two-dimensional cultures, organoids incorporate more physiologically relevant cell-cell and cell-matrix interactions, and are a better reflection of the complex network found in vivo.With significant opportunities for studies of human-specific disease mechanisms, personalized medicine, drug discovery, pharmacokinetic profiling and regenerative medicine, organoids are being pursued across a range of disciplines. Many anticipate that these cell culture models will result in more efficient translation of research into clinical success. In this article, we explore the various types of organoids under development and shine a spotlight on some of the different approaches to organoids in cancer research.

Organoids can be derived from pluripotent stem cells (including embryonic stem cells or induced pluripotent stem cells) or neonatal or adult stem cells from healthy or diseased tissue.1,2 Cancer organoids have been generated from a range of human cancer tissues and cell lines including colon, pancreas, prostate, liver, breast, bladder and lung.6-12 This year, a research group led by Hongjun Song, Professor of Neuroscience at the Perelman School of Medicine at the University of Pennsylvania, published a report in Cell detailing methods for the rapid generation of patient-derived glioblastoma organoids.13Fresh tumor specimens were removed from 53 patient cases to produce microdissected tumor pieces that could survive, develop a spherical morphology and continuously grow in culture for at least two weeks (Figure 1). The production of glioblastoma organoids was achieved while maintaining a high level of similarity between the organoids and their parental tumors, with the expression levels of specific markers showing stability over long-term culture (48 weeks). Importantly, native cell-cell interactions were preserved by avoiding mechanical and enzymatic single-cell dissociation of the resected tumor. As Song explains, this was achieved on a clinically relevant timescale: Normally, the treatment for glioblastoma patients starts one month after surgery. The idea is that glioblastoma organoids can be generated within two weeks and subjected to testing of different treatment strategies to come up with the best option for a personalized treatment strategy.

Figure 1: Glioblastoma organoid generation, from fresh tumor pieces to frozen spherical organoids. Image used with permission from Jacob et al. 2020.One concern with organoid formation and expansion is the potential variability of the serum or Matrigel that can exist across batches and sources, creating variable exogenous factors that could cause the organoid to divert. This ultimately compromises reproducibility, a major bottleneck of current organoid systems.2,13 To avoid this source of error, Songs group used an optimized and defined medium devoid of variable factors that could contribute to the clonal selection of specific cell populations in culture.Glioblastoma is the most prevalent primary malignant brain tumor in adults,14 and having glioblastoma organoids available for research would present significant opportunities, explains Song: They can be used to test different drugs based on mutation profiles and to investigate mechanisms underlying tumor progression, drug sensitivity and resistance. While the accuracy of these predictions would need to be verified, researchers hope that patient-derived organoids will be used to help inform oncologists, accelerate drug discovery, and lead to better clinical trial design.Live-Cell Monitoring: Optimizing Workflows for Advanced Cell Models

As cell-based assays become technically more complex, the need to holistically capture dynamic and sometimes subtle cellular events becomes ever more important. By providing real-time imaging data of cellular events without disturbing the sample during the cell culture workflow, live-cell monitoring can support the optimization of these advanced models. Download this whitepaper to discover how live-cell monitoring can support such optimization, with a breadth of applications.

Sponsored Content

For this to be achieved, techniques for the culture and genetic manipulation of primary human hepatocytes need to be refined. This has mostly been pursued through the culture of liver progenitors or fetal hepatocytes, which facilitate studies of liver cancers related to stem cells.16-18 To address the need for organoids derived from functional hepatocytes, researchers across 14 universities, research institutes and hospitals in China and Japan collaborated to genetically engineer reprogrammed human hepatocytes.18 The study, published in Nature Cell Biology, details the successful generation of organoids that represented two major types of liver cancer (hepatocellular carcinoma: HCC and intra-hepatic cholangiocarcinoma: ICC), derived from directly reprogrammed human hepatocytes (hiHeps).Lead author Lulu Sun, of the Shanghai Institute of Biochemistry and Cell Biology at the University of Chinese Academy of Sciences, provides an overview of how the liver cancer organoids were developed: Genomic aberrations begin to occur during cancer initiation, and the normal cells gradually became malignant. We modeled this process by introducing HCC/ICC-related oncogenes into the organoids with a lentivirus. Oncogenes were selected based on their mutation frequency and previous results in animals. Sun notes that gradual changes in cell and organoid morphology were observed in vitro, along with changes in the expression of HCC-related markers, before the organoids were transplanted to inspect their malignancy in vivo: We cultured these organoids in vitro for about two weeks and transplanted them into the liver lobule of immunodeficient mice. Six to eight weeks later, they formed features identical to HCCs.Even though numerous oncogenes have been identified through whole genome sequencing, it has been difficult to determine whether they can drive the initiation of human liver cancers. Ultrastructural analyses revealed that c-Myc, a well-known oncogene, induced HCC-initiation and a unique cellular phenotype in the hiHep organoids. In these cells, mitochondria were in unusually close contact with endoplasmic reticulum membranes. This excessive coupling between mitochondria and the endoplasmic reticulum (referred to as a MAM phenotype) was shown to facilitate HCC-initiation and when blocked, prevented the progression towards HCC, says Sun: Not only were the expression levels of HCC-related genes in organoids reduced, but significantly reduced cancers were formed in mice.Resolving these alterations in mitochondrial organization represents a new potential approach to liver cancer therapies, and possibly others, Sun explains: Restoration of a proper MAM interface may be a useful approach in preventing c-MYC-initiated HCCs. In addition, recently, an increasing number of works captured ultrastructural alterations, including MAMs, in the course of diseases including Alzheimer's disease and fatty liver diseases. Our results showed that the alterations between communications of organelles may also contribute to the cancer initiation process.All About Organoids

Organoids are 3D cell clusters with the structural and functional features of an organ, and can be generated from induced pluripotent stem cells (iPSCs) or adult stem cells acquired from a specific patient. Consequently, organoids make it possible to study the impact of a drug on a specific disease, even a persons own disease they are changing the face of research and medicine as we know it. Download this eBook to discover more about organoids including their analysis and how they are effecting personalized medicine.

Sponsored Content

2. Huch, M., Knoblich, J. A., Lutolf, M. P, et al. (2017). The hope and the hype of organoid research. Development, 144(6), 938941. https://doi.org/10.1242/dev.150201

3. Hutchinson, L., & Kirk, R. (2011). High drug attrition ratesWhere are we going wrong? Nature Reviews Clinical Oncology, 8(4), 189190. https://doi.org/10.1038/nrclinonc.2011.34

4. Fan, H., Demirci, U., Chen, P. (2019). Emerging organoid models: Leaping forward in cancer research. Journal of Hematology & Oncology, 12(142). https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0832-4

5. Drost, J., Clevers, H. (2018). Organoids in cancer research. Nature Reviews Cancer, 18(7), 407418. https://doi.org/10.1038/s41568-018-0007-6

6. van de Wetering, M., Francies, H. E., Francis, J. M., et al. (2015). Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients. Cell, 161(4), 933945. https://doi.org/10.1016/j.cell.2015.03.053

7. Boj, S. F., Hwang, C.-I., Baker, L. A., et al. (2015). Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell, 160(12), 324338. https://doi.org/10.1016/j.cell.2014.12.021

8. Puca, L., Bareja, R., Prandi, D., et al. (2018). Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 9(1), 2404. https://doi.org/10.1038/s41467-018-04495-z

9. Broutier, L., Mastrogiovanni, G., Verstegen, M. M., et al. (2017). Human primary liver cancerderived organoid cultures for disease modeling and drug screening. Nature Medicine, 23(12), 14241435. https://doi.org/10.1038/nm.4438

10. Sachs, N., de Ligt, J., Kopper, O., et al. (2018). A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell, 172(12), 373-386.e10. https://doi.org/10.1016/j.cell.2017.11.010

11. Lee, S. H., Hu, W., Matulay, J. T., et al. (2018). Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 173(2), 515-528.e17. https://doi.org/10.1016/j.cell.2018.03.017

12. Kim, M., Mun, H., Sung, C. O., et al. (2019). Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications, 10(1), 3991. https://doi.org/10.1038/s41467-019-11867-6

13. Jacob, F., Salinas, R. D., Zhang, D. Y., et al. (2020). A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell, 180(1), 188-204.e22. https://doi.org/10.1016/j.cell.2019.11.03

14. Ostrom, Q. T., Gittleman, H., Truitt, G., et al. (2018). CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 20112015. Neuro-Oncology, 20(suppl_4), iv1iv86. https://doi.org/10.1093/neuonc/noy131

15. Bruix, J., Han, K.-H., Gores, G., et al. (2015). Liver cancer: Approaching a personalized care. Journal of Hepatology, 62(1), S144S156. https://doi.org/10.1016/j.jhep.2015.02.007

16. Hu, H., Gehart, H., Artegiani, B., et al. (2018). Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids. Cell, 175(6), 1591-1606.e19. https://doi.org/10.1016/j.cell.2018.11.013

17. Zhang, K., Zhang, L., Liu, W., et al. (2018). In Vitro Expansion of Primary Human Hepatocytes with Efficient Liver Repopulation Capacity. Cell Stem Cell, 23(6), 806-819.e4. https://doi.org/10.1016/j.stem.2018.10.018

18. Sun, L., Wang, Y., Cen, J., et al, (2019). Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nature Cell Biology, 21(8), 10151026. https://doi.org/10.1038/s41556-019-0359-5

19. Madhavan, M., Nevin, Z. S., Shick, H. E., et al. (2018). Induction of myelinating oligodendrocytes in human cortical spheroids. Nature Methods, 15(9), 700706. https://doi.org/10.1038/s41592-018-0081-4

20. Post, Y., Puschhof, J., Beumer, J., et al. (2020). Snake Venom Gland Organoids. Cell, 180(2), 233-247.e21. https://doi.org/10.1016/j.cell.2019.11.038

21. Calandrini, C., Schutgens, F., Oka, R., et al. (2020). An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature Communications, 11(1), 1310. https://doi.org/10.1038/s41467-020-15155-6

22. Subramanian, A., Sidhom, E.-H., Emani, M., et al. (2019). Single cell census of human kidney organoids shows reproducibility and diminished off-target cells after transplantation. Nature Communications, 10(1), 5462. https://doi.org/10.1038/s41467-019-13382-0

Read more from the original source:
Organoids: Exploring Liver Cancer Initiation and the Possibilities of Personalized Glioblastoma Treatment - Technology Networks